// App-Quantinova.ai

e14129 : ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.

Researchers

Presenter

  • Niranjan Sathyanarayana Rao

Principal Investigators

  • Anthony W. Tolcher

  • Kyriakos P. Papadopoulos

  • Drew W. Rasco

  • Naomi B. Haas

  • Allan J. Pantuck

  • Louis J. Denis

  • Robert Dreicer

Medical Centers

  • Asana Biosciences LLC, Bridgewater, NJ

  • START San Antonio, San Antonio, TX

  • START Center for Cancer Care, San Antonio, TX

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • UCLA Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA

  • Asana Biosciences LLC, Bridgewater, NJ

  • University of Virginia school of medicine, Charlottesville, VA

Locations

  • United States

Companies

  • Asana BioSciences, L

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Adrenocorticotropic hormone

  • Prostate specific antigen

  • Cortisol

  • Cytochrome P450 Family 17 subfamily A member 1

  • Follicle-stimulating hormone

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Prednisone

  • Androgen Tear

  • ASN-001

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT02349139

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved